EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Clinical trials for EGFR POSITIVE NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new EGFR POSITIVE NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for EGFR POSITIVE NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for lung cancer patients when standard drugs fail
Disease control OngoingThis study is testing the safety and effectiveness of combining an experimental drug called APG-1252 with an existing lung cancer drug, osimertinib. It is for people with advanced EGFR-positive non-small cell lung cancer whose disease has progressed after previous treatments. The…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Can lung cancer patients skip a drug break for radiation?
Disease control OngoingThis study aims to find out if it's safe and effective for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) to continue taking their daily oral medication, osimertinib, while also receiving radiation therapy. It involves 42 participants who need radiation…
Matched conditions: EGFR POSITIVE NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: AIO-Studien-gGmbH • Aim: Disease control
Last updated Apr 01, 2026 14:43 UTC